Chezy Barenholz
VICE PRESIDENT
pharmaceutical
Redhill Biopharma
Israel
Biography
Prof. Barenholz is a renowned specialist in biochemistry, biophysics, nanotechnology and cancer, with 46 years of experience in research and development. Prof. Barenholz is the head of the Laboratory of Membrane and Liposome Research at the Department of Biochemistry, the Hebrew University–Hadassah Medical School, Jerusalem, Israel. Prof. Barenholz is the author of over 350 publications and the editor of academic journals and books. He is the co-inventor of over 30 patent families, two of which underlie Doxil® for the treatment of breast and ovarian cancer. Doxil® is the first liposomal drug and the first nano-medicine that was approved by the FDA.
Research Interest
Pharmaceutical science
